1. In this prospective cohort study of patients with multiple sclerosis, upfront use of highly-efficacious disease modifying therapies (DMTs) compared ...
1. In this case-control cohort study, treatment with glatiramer acetate, interferon-beta, fingolimod, alemtuzumab, and natalizumab all led to reduced conversion ...
1. In this case-control cohort study, treatment with glatiramer acetate, interferon-beta, fingolimod, alemtuzumab, and natalizumab all led to reduced conversion ...
2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.
